Rep. Ro Khanna disclosed roughly $24,000 in transactions involving medical device maker ZBH — Zimmer Biomet Holdings — executed across both his own account and a spouse’s account on Feb. 17, 2026, according to newly filed congressional trading records.
The California Democrat reported a cluster of three trades in the orthopedic implant manufacturer on the same day, including both purchases and a sale in a spouse’s account. The filings place each individual transaction in the $1,000 to $15,000 range.
Zimmer Biomet, which trades on the New York Stock Exchange and carries a market capitalization of about $18.5 billion, is a major producer of knee and hip replacement implants as well as surgical tools used in joint reconstruction. The company’s shares recently traded around $93.20. Its financial performance is closely tied to procedure volumes for elective orthopedic surgeries and long-term demand driven by aging populations.
Details of the Feb. 17 trades
- Feb. 17, 2026 — Buy: $1,000–$15,000 (account owner listed as DC)
- Feb. 17, 2026 — Sell: $1,000–$15,000 (spouse)
- Feb. 17, 2026 — Buy: $1,000–$15,000 (spouse)
The sequence suggests a rebalancing or repositioning of the household’s exposure to the orthopedic device manufacturer rather than a straightforward accumulation or exit.
Congressional filings disclose only value ranges rather than exact amounts, meaning the combined activity could total anywhere from roughly $3,000 to $45,000. Based on midpoint estimates commonly used in disclosure analyses, the transactions amount to about $24,000 in traded value.
A widely held healthcare name on Capitol Hill
Zimmer Biomet is not an obscure pick among lawmakers. At least 15 members of Congress have reported trading the stock, reflecting its position as a major U.S. medical technology company with stable demand tied to demographic trends.
The company generates most of its revenue from joint reconstruction products, including knee and hip replacement systems. Investors often track hospital procedure volumes, new product launches, and hospital capital spending cycles when evaluating the stock. Elective surgeries delayed during the COVID-era backlog have also been a major theme shaping orthopedic device demand in recent years.
While Khanna serves on the House Armed Services Committee and the House Oversight and Government Reform Committee, his committee assignments do not directly oversee orthopedic device regulation or Medicare reimbursement policy, areas that tend to influence medical device companies’ revenue outlook.
A highly active congressional trader
The ZBH transactions are a small slice of Khanna’s extensive disclosure history. Financial filings show 19,625 career trades reported under his name or family accounts, placing him among the more active traders in Congress.
Under the STOCK Act, lawmakers must disclose stock trades within a specified reporting window, allowing the public to monitor potential conflicts and investment activity by elected officials. Those disclosures feed databases tracking the latest congressional trades across Capitol Hill.
For Zimmer Biomet investors, the Feb. 17 transactions highlight continued congressional exposure to the orthopedic device sector — a market shaped by demographics, surgical innovation, and global healthcare spending trends.